Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Primary Open Angle Glaucoma, Cataract
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more

Conditions: Glaucoma; Drugs
Interventions: CATS Tonometer, Latanoprost; Device · Drug
Lead sponsor: Intuor Technologies, Inc.; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Latanoprost; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glaucoma
Interventions: Collection of trabecular meshwork tissue during surgery; Other
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: brimonidine 0.1% (Alphagan® P); Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma
Interventions: RS3000Adv; Device
Lead sponsor: Doheny Image Reading Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Glaucoma
Interventions: Model iS3 three-stent trabecular micro-bypass system; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 45 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System, iStent inject; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Dothan, Alabama • Vineland, New Jersey

Conditions: Ocular Hypertension
Interventions: bimatoprost/timolol fixed combination; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma
Interventions: HOCD; Device
Lead sponsor: Benjamin Frankfort, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID); Drug
Lead sponsor: Cornerstone Health Care, PA; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma
Interventions: Pilocarpine, Prednisolone, Ofloxacin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions: QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%); Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Glaucoma
Interventions: MINIject™ Implant; Device
Lead sponsor: iSTAR Medical; Industry
Eligibility: 46 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 28
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 20 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
Interventions: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery; Combination Product · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 45 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kenosha, Wisconsin

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, LUMIGAN; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more

Conditions: Glaucoma
Interventions: endoscopic goniotomy; Device
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Week to 3 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma
Interventions: Xal-Ease device to be used with Xalatan eye drops; Device
Lead sponsor: Augusta University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Glaucoma
Interventions: Prednisolone 1%, Ketorolac, Artificial Tears; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Miami, Florida • Pittsburgh, Pennsylvania

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%, Placebo Comparator; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Rochester, Minnesota • Durham, North Carolina

Conditions: Open-Angle Glaucoma
Interventions: XEN45 (Glaucoma Gel Stent); Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more

Search by objective public record fields.

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

24-hour IOP-lowering Effect of Brimonidine 0.1%

Testing Latest Version of NidekRS3000Adv

Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory Glaucoma

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

Social Worker in an Eye-Care Service

Assessing Ocular Surface Changes After Changing Glaucoma Medications

Pilocarpine Use After Kahook Goniotomy

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Endoscopic Goniotomy for Infantile Glaucoma

Effects of Xal-Ease on Patient Compliance With Xalatan

Steroids After Laser Trabeculoplasty for Glaucoma

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma